Exact Mass: 348.04079519999993
Exact Mass Matches: 348.04079519999993
Found 72 metabolites which its exact mass value is equals to given mass value 348.04079519999993,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Inosine 5'-monophosphate (IMP)
Inosinic acid, also known as inosine monophosphate, IMP, 5-inosinate or 5-IMP, belongs to the class of organic compounds known as purine ribonucleoside monophosphates. These are nucleotides consisting of a purine base linked to a ribose to which one monophosphate group is attached. IMP is also classified as a nucleotide (a nucleoside monophosphate). Inosinic acid exists in all living species, ranging from bacteria to plants to humans. IMP is widely used as a flavor enhancer. In the food industry it is known as E number reference E630. Inosinic acid can be converted into various salts including disodium inosinate (E631), dipotassium inosinate (E632), and calcium inosinate (E633). These three inosinate compounds are used as flavor enhancers for the basic taste umami. These inosinate salts are mostly used in soups, sauces, and seasonings for the intensification and balance of the flavor of meat. Inosinic acid is typically obtained from chicken byproducts or other meat industry waste. Inosinic acid or IMP is important in metabolism. It is the ribonucleotide of hypoxanthine and the first nucleotide formed during the synthesis of purine nucleotides. It can also be formed by the deamination of adenosine monophosphate by AMP deaminase. GMP is formed by the inosinate oxidation to xanthylate (XMP). Within humans, inosinic acid participates in a number of enzymatic reactions. In particular, inosinic acid can be converted into phosphoribosyl formamidocarboxamide; which is catalyzed by the bifunctional purine biosynthesis protein. In addition, inosinic acid can be converted into xanthylic acid; which is catalyzed by the enzyme inosine-5-monophosphate dehydrogenase 1. Origin: Microbe; Formula(Parent): C10H13N4O8P; Bottle Name:Inosine-5-monophosphate; PRIME Parent Name:Inosine-5-monophosphate; PRIME in-house No.:0258, Purines A purine nucleotide which has hypoxanthine as the base and one phosphate group esterified to the sugar moiety. COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, COVID-19 Disease Map Acquisition and generation of the data is financially supported in part by CREST/JST. relative retention time with respect to 9-anthracene Carboxylic Acid is 0.056 relative retention time with respect to 9-anthracene Carboxylic Acid is 0.057 Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Inosinic acid is an endogenous metabolite.
2-O-(6-Phospho-alpha-mannosyl)-D-glycerate
2-O-(6-Phospho-alpha-mannosyl)-D-glycerate is an alpha-D-mannosylglycerate (MG) that is an intermediate in 2-O-alpha-mannosyl-D-glycerate degradation. It can be generated from 2-O-alpha-mannosyl-D-glycerate via the enzyme 2-O-alpha-mannosyl-D-glycerate transporting phosphotransferase system (mngA). 2-O-Alpha-mannosyl-D-glycerate is a natural extremolyte identified in microorganisms growing under extremely high temperatures up to 100 oC, and had been shown to protect proteins against various stress conditions such as heat, freezing, thawing, and drying. MG that is naturally occurring hyperthermophilic osmolytes, could be potential drug candidates or lead compounds against alpha,beta aggregation associated with Alzheimers disease(PMID: 18304694). In most organisms MG is produced from guanosine pyrophosphate mannose (GDP-alpha-D-mannose) via mannosyl-3-phosphoglycerate in two steps, catalyzed by the enzymes mannosyl-3-phosphoglycerate synthase and mannosyl-3-phosphoglycerate phosphatase. [HMDB] 2-O-(6-Phospho-alpha-mannosyl)-D-glycerate is an alpha-D-mannosylglycerate (MG) that is an intermediate in 2-O-alpha-mannosyl-D-glycerate degradation. It can be generated from 2-O-alpha-mannosyl-D-glycerate via the enzyme 2-O-alpha-mannosyl-D-glycerate transporting phosphotransferase system (mngA). 2-O-Alpha-mannosyl-D-glycerate is a natural extremolyte identified in microorganisms growing under extremely high temperatures up to 100 oC, and had been shown to protect proteins against various stress conditions such as heat, freezing, thawing, and drying. MG that is naturally occurring hyperthermophilic osmolytes, could be potential drug candidates or lead compounds against alpha,beta aggregation associated with Alzheimers disease(PMID: 18304694). In most organisms MG is produced from guanosine pyrophosphate mannose (GDP-alpha-D-mannose) via mannosyl-3-phosphoglycerate in two steps, catalyzed by the enzymes mannosyl-3-phosphoglycerate synthase and mannosyl-3-phosphoglycerate phosphatase.
2-keto-3-deoxy-D-glycero-D-galacto-nononate 9-phosphate
(2R)-2-(alpha-D-glucopyranosyloxy)-3-(phosphonooxy)propanoic acid
Inosine 2'-phosphate
Inosine 2-phosphate is an inosine nucleotide containing a pyrophosphate group esterified to C2 of the sugar moiety. Inosine 2-phosphate is a product of 2,3-cyclic-nucleotide 3-phosphodiesterase (EC 3.1.4.37). This enzyme (also called CNP) catalyzes the chemical reaction: nucleoside 2,3-cyclic phosphate + H2O <-> nucleoside 2-phosphate. 2,3-cyclic nucleotide 3-phosphodiesterase is a myelin-associated enzyme that makes up 4\\% of total CNS myelin protein, and is thought to undergo significant age-associated changes. The absence of CNP causes axonal swelling and neuronal degeneration. [HMDB] Inosine 2-phosphate is an inosine nucleotide containing a pyrophosphate group esterified to C2 of the sugar moiety. Inosine 2-phosphate is a product of 2,3-cyclic-nucleotide 3-phosphodiesterase (EC 3.1.4.37). This enzyme (also called CNP) catalyzes the chemical reaction: nucleoside 2,3-cyclic phosphate + H2O <-> nucleoside 2-phosphate. 2,3-cyclic nucleotide 3-phosphodiesterase is a myelin-associated enzyme that makes up 4\\% of total CNS myelin protein, and is thought to undergo significant age-associated changes. The absence of CNP causes axonal swelling and neuronal degeneration.
Glucose-6-phosphate lactate
[(2R,5R)-3,4-Dihydroxy-5-(6-oxo-1H-purin-9-yl)oxolan-2-yl]methyl dihydrogen phosphate
Flavour enhancer
Cloxazolam, (R)-
N - Nervous system > N05 - Psycholeptics > N05B - Anxiolytics > N05BA - Benzodiazepine derivatives C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent
2-[(4-Chlorophenyl)sulfonyl]-3-[(4,6-dimethylpyrimidin-2-yl)amino]acrylonitrile
C15H13ClN4O2S (348.04477080000004)
Isobutyric acid (2,2:5,2-terthiophen-5-yl)methyl ester
5-acetoxymethylen-2-(4-acetoxy-but-3-inyl)-dithiophene|5-acetoxymethylen-2-<4-acetoxy-but-3-inyl>-dithiophene|Di-Ac-4-[5-(Hydroxymethyl)-[2,2-bithiophen-5-yl]]-3-butyn-1-ol
Di-Ac-4-[5-Methyl-[2,2-bithiophen]-5-yl]-3-butyne-1,2-diol
(8beta)-10-bromo-3-chloro-2,7-epoxychamigr-9-en-8-ol|rel-(2R,3S,5aR,9S,9aR)-7-bromo-3-chloro-2,3,4,5,9,9a-hexahydro-3,6,6,9a-tetramethyl-6H-2,5a-methano-1-benzoxepin-9-ol
1-Hydroxy-3-methyl-8,10-dimethoxy-9-chlorodibenz[b,e]oxepin-6,11-dione
Inosinic acid
COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials, COVID-19 Disease Map Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Inosinic acid is an endogenous metabolite.
3-(trimethylsilyl)-2-naphthyl trifluoromethanesulfonate
1-(4-chloro-3-isocyanatobenzenesulfonyl)-1,2,3,4-tetrahydroquinoline
C16H13ClN2O3S (348.0335378000001)
N-(4-aminobutyl)-5-chloro-2-naphthalenesulfonamide hydrochloride
1,2,3,4,5,6-Cyclohexanehexacarboxylic acid
C12H12O12 (348.03287520000003)
N-(3-chloro-4-fluorophenyl)-7-methoxy-6-nitroquinazolin-4-amine
C15H10ClFN4O3 (348.04254319999995)
4-Oxo-2-phenyl-4H-chromen-3-yl 2-thiophenecarboxylate
3-(perfluorobutyl)-2-hydroxypropyl acrylate
C10H9F9O3 (348.04079519999993)
{[4-Amino-2-(3-chloroanilino)-1,3-thiazol-5-YL](4-fluorophenyl)methanone
Tolestan
N - Nervous system > N05 - Psycholeptics > N05B - Anxiolytics > N05BA - Benzodiazepine derivatives C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent
3-deoxy-D-glycero-beta-D-galacto-nonulosonic acid 9-phosphate
A ketoaldonic acid phosphate that is 3-deoxy-D-glycero-beta-D-galacto-nonulosonic acid carrying a monophosohate substituent at position 9.
[5-(2,6-dioxo-3H-purin-9-yl)-3-hydroxyoxolan-2-yl]methyl dihydrogen phosphate
(2R)-3-phosphonooxy-2-[(2R,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropanoic acid
[2,3,4,5-Tetrahydroxy-6-(phosphonooxymethyl)oxan-2-yl] 2-hydroxypropanoate
4-Chloro-6-[5-(4-ethoxyphenyl)-1,2,3-thiadiazol-4-yl]benzene-1,3-diol
C16H13ClN2O3S (348.0335378000001)
5-[(3-chlorophenoxy)methyl]-N-(4-methyl-2-thiazolyl)-2-furancarboxamide
C16H13ClN2O3S (348.0335378000001)
4-chloro-3-nitrobenzaldehyde N-(4-methylphenyl)thiosemicarbazone
C15H13ClN4O2S (348.04477080000004)
4-[(2-oxo-3H-1,3-benzoxazol-6-yl)sulfonylamino]benzoic acid methyl ester
C15H12N2O6S (348.04160520000005)
N-[4-(4-fluorophenyl)-2-thiazolyl]-4-methylbenzenesulfonamide
C16H13FN2O2S2 (348.04024499999997)
N-[1-[(2-bromophenyl)methyl]-2-oxo-3-pyridinyl]butanamide
C16H17BrN2O2 (348.04733219999997)